HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it will host an in-person analyst day at the New York Marriott Marquis on February 12, 2025, at 2:00 p.m. ET.
The event will feature presentations from the following members of the Company's management:
The event will highlight FibroBiologics’ research and development strategy for advancing fibroblast-based therapeutics to address chronic diseases.
A live Q&A session will follow the formal presentations. An audio recording of the presentation and Q&A will be available under the investor section of the FibroBiologics website after the event.
In addition, FibroBiologics will be presenting at the 2025 BIO CEO & Investor Conference in New York, NY, from February 10-11. Details of the event are as follows:
Date: Tuesday, February 11
Time: 11:15 a.m. ET
Location: The New York Marriott Marquis
Track: Plymouth Room
To learn more about the event, please visit https://bcic.bio.org/, or to schedule one-on-one meetings, please email This email address is being protected from spambots. You need JavaScript enabled to view it..
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.81 |
| Daily Change: | -0.04 -4.35 |
| Daily Volume: | 134,689 |
| Market Cap: | US$28.620M |
April 02, 2025 March 31, 2025 March 04, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
